CRISPR Base Editing Correction of TGFBI Mutations in Autosomal Dominant Corneal Dystrophies

Jue Chen; Connor W Davison; James H. Ellis; Bridget Blevins; William Presley; Mason Myers; Dejuan Kong; Zhonggang Hou; Shahzad I. Mian; Lev Prasov; Yan Zhang

doi:10.1167/iovs.67.2.60

February 27, 2026Investigative Ophthalmology & Visual ScienceOpen Access

CRISPR Base Editing Correction of TGFBI Mutations in Autosomal Dominant Corneal Dystrophies

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to evaluate the potential of CRISPR base editing as a treatment for TGFBI mutations in corneal dystrophies.
Utilized CRISPR adenine base editing in laboratory settings
Targeted TGFBI mutations associated with corneal dystrophies
Assessed safety and feasibility of the technique
Successful correction of TGFBI mutations observed
Indicated safety of the CRISPR base editing approach
Promising results for future preclinical testing

Implication

Demonstrates the efficacy of base editing for correcting TGFBI mutations in corneal dystrophies, suggesting a novel treatment approach.

Abstract

Our study demonstrates the feasibility and safety of CRISPR adenine base editing as a new therapeutic strategy for correcting common TGFBI mutations in corneal dystrophies, paving the way for further preclinical testing.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69a3d7eeec16d51705d2e688 https://doi.org/10.1167/iovs.67.2.60

View Full Paper

Ask AI

Bookmark

Share

CRISPR Base Editing Correction of TGFBI Mutations in Autosomal Dominant Corneal Dystrophies

Key Points

Implication

Abstract

Discussion

Cite This Study

CRISPR Base Editing Correction of TGFBI Mutations in Autosomal Dominant Corneal Dystrophies

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading